The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies

Brain

Volumn 133, Issue 12, 2010, Pages 3724-3733

  Beyer, Katrin ^a,b   Domingo Sàbat, Montserrat ^a   Santos, Cristina ^c   Tolosa, Eduardo ^d   Ferrer, Isidro ^b   Ariza, Aurelio ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b ICS Institute of Neuropathology   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Dementia with lewy bodies; Differential isoform expression; mRNA expression; synuclein; synuclein

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN TRANSCRIPT SNCA140; BETA SYNUCLEIN; BETA SYNUCLEIN TRANSCRIPT VARIANT 1; BETA SYNUCLEIN TRANSCRIPT VARIANT 2; MESSENGER RNA; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DIFFUSE LEWY BODY PATHOLOGY AND CONCOMITANT ALZHEIMER PATHOLOGY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TEMPORAL CORTEX; WESTERN BLOTTING;

EID: 79951936156     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq275     Document Type: Article

References (41)

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-92. (Pubitemid 36314364)
2. Beyer K, Domingo-Sàbat M, Humbert J, Carrato C, Ferrer I, Ariza A. Differential expression of alpha-synucleln, parkin, and synphllln-1 isoforms In Lewy body disease. Neurogenetics 2008a; 9: 163-72.
3. Beyer K, Domingo-Sábat M, Lao JI, Carrato C, Ferrer I, Ariza A. Identification and characterization of a new alpha-synucleln isoform and its role in Lewy body diseases. Neurogenetics 2008b; 9: 15-23. (Pubitemid 351170166)
4. Beyer K, Humbert J, Ferrer A, Lao JI, Carrato C, López D, et al. Low alpha-synuclein 126 mRNA levels In dementia with Lewy bodies and Alzheimer disease. Neuroreport 2006; 17: 1327-30. (Pubitemid 44337076)
5. Beyer K, Lao JI, Carrato C, Mate JL, López D, Ferrer I, et al. Differential expression of alpha-synucleln isoforms in dementia with Lewy bodies. Neuropathol Appl Neurobiol 2004; 30: 601-7. (Pubitemid 39564179)
6. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211. (Pubitemid 36007810)
7. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
8. Braak H, Braak E. Diagnostic criteria for neuropathological assessment of Alzheimer's disease. Neurobiol Aging 1997; 18: S85-S88. (Pubitemid 27454703)
9. Caballol N, Martí MJ, Tolosa E. Cognitive dysfunction and dementia In Parkinson disease. Mov Disord 2007; 22: S358-S366. (Pubitemid 350134189)
10. da Costa CA, Masliah E, Checler F. Beta-synucleln displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-lnduced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease. J Biol Chem 2003; 278: 37330-5. (Pubitemid 37175250)
11. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 2009; 106: 13010-15.
12. Durrenberger PF, Fernando S, Kashefi SN, Ferrer I, Hauw JJ, Seilhean D, et al. Effects of antemortem and postmortem variables on human brain mRNA quality: a BrainNet Europe study. J Neuropathol Exp Neurol 2010; 69: 70-81.
13. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-37. (Pubitemid 37443310)
14. Ferman TJ, Boeve BF. Dementia with Lewy bodies. Neurol Clin 2007; 25: 741-60. (Pubitemid 47058869)
15. Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, et al. Genetic variability in the SNCA gene influences alpha-synuclein levels In the blood and brain. FASEB J 2008; 22: 1327-34. (Pubitemid 351656774)
16. Hanyu H, Sato T, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Differences in clinical course between dementia with Lewy bodies and Alzheimer's disease. Eur J Neurol 2009; 16: 212-17.
17. Hashimoto M, Bar-On P, Ho G, Takenouchi T, Rockenstein E, Crews L, et al. Beta-synuclein regulates Akt activity In neuronal cells. A possible mechanism for neuroprotection In Parkinson's disease. J Biol Chem 2004; 279: 23622-9. (Pubitemid 38685677)
18. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an antiparkinsonian factor. Neuron 2001; 32: 213-23. (Pubitemid 33030190)
19. Israeli E, Sharon R. Beta-synuclein occurs in vivo In lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein. J Neurochem 2009; 108: 465-74.
20. Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 2008a; 116: 1-16.
21. Jellinger KA. Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008b; 67: 484-5.
22. Jellinger KA. A critical evaluation of current staging of alpha-synucleln pathology in Lewy body disorders. Biochim Biophys Acta 2009; 1792: 730-40.
23. Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 2006; 112: 253-60.
24. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008; 67: 155-61.
25. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27: 1405-10.
26. Livak KJ, Schmlttgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8. (Pubitemid 34164012)
27. Maroteaux L, Campanelli JT, Serieller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988; 8: 2804-15.
28. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-72. (Pubitemid 43970103)
29. Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, Takahashi H, et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004; 63: 805-11. (Pubitemid 39297638)
30. Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shaml R, Allsop D, et al. Detection of elevated levels of soluble alpha-synuclein oligomers In post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009; 132: 1093-101.
31. Park JY, Lansbury PT Jr. Beta-synuclein Inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 2003; 42: 3696-700.
32. Popova T, Mennerich D, Weith A, Quast K. Effect of RNA quality on transcript intensity levels In microarray analysis of human post-mortem brain tissues. BMC Genomics 2008; 9: 91.
33. Rutledge RG, Côté C. Mathematics of quantitative kinetic PCR and the application of standard curves. Nucleic Acids Res 2003; 31: e93.
34. Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H. Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's C T difference" formula. J Mol Med 2006; 84: 901-10.
35. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-8. (Pubitemid 351818697)
36. Shults CW. Lewy bodies. Proc Natl Acad Sci USA 2006; 103: 1661-8. (Pubitemid 43228751)
37. Snyder H, Mensah K, Hsu C, Hashimoto M, Surgucheva IG, Festoff B, et al. beta-synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein. J Biol Chem 2005; 280: 7562-9. (Pubitemid 40349648)
38. Spillantinl MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein In filamentous Inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998; 95: 6469-73. (Pubitemid 28249037)
39. Sung YH, Eliezer D. Residual structure, backbone dynamics, and interactions within the synuclein family. J Mol Biol 2007; 372: 689-707. (Pubitemid 47313488)
40. Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, et al. Dynamics of alpha-synucleln aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J 2007; 274: 1862-77. (Pubitemid 46426920)
41. Uversky VN, Li J, Souillac P, Millett IS, Doniach S, Jakes R, et al. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synuclein. J Biol Chem 2002; 277: 11970-8. (Pubitemid 34952757)